TriSalus Life Sciences (NASDAQ:TLSI) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.23) by 69.57 percent. This is a 35 percent increase over losses of $(0.60) per share from the same period last year. The company reported quarterly sales of $9.17 million which beat the analyst consensus estimate of $9.04 million by 1.45 percent. This is a 41.97 percent increase over sales of $6.46 million the same period last year.